HLA
NGM

Hamilton Lane Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Hamilton Lane Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-37,503
Closed -$481K – 77
2022
Q2 		$481K Buy
+37,503
New +$519K 0.19% 43
2021
Q4 		– Sell
-62,500
Closed -$1.31M – 107
2021
Q3 		$1.31M Buy
+62,500
New +$1.38M 0.22% 42

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hamilton Lane Advisors's NGM Position: Q3 2022 in Review

Hamilton Lane Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2022, closing a stake of 37,503 shares — an estimated $481K sold.

Hamilton Lane Advisors first reported a position in NGM in Q3 2021 and held it in 2 quarters. The position peaked at $1.31M in Q3 2021. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

  • Hamilton Lane Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Hamilton Lane Advisors sold 37,503 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $481K.
  • Hamilton Lane Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Hamilton Lane Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.31M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Hamilton Lane Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.